MedPath

Clorazepic acid

Generic Name
Clorazepic acid
Drug Type
Small Molecule
Chemical Formula
C16H11ClN2O3
CAS Number
23887-31-2
Unique Ingredient Identifier
D51WO0G0L4

Overview

Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization. The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence. In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. Clorazepate and its active metabolite, nordiazepam, are present in breast milk.

Background

Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. Following administration, clorazepate is rapidly converted to nordiazepam (N-desmethyldiazepam), its active metabolite, before entering systemic circulation. Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal hyperpolarization. The concomitant use of clorazepate and opioids may result in profound sedation, respiratory depression, coma, and death. Also, the use of clorazepate exposes users to users to the risks of abuse, misuse, and addiction, and its continued use may lead to significant physical dependence. In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. Clorazepate and its active metabolite, nordiazepam, are present in breast milk.

Indication

Clorazepate is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. It is also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.

Associated Conditions

  • Acute Alcohol Withdrawal
  • Anxiety Acute
  • Generalized Anxiety Disorder
  • Partial-Onset Seizures

FDA Approved Products

CLORAZEPATE DIPOTASSIUM
Manufacturer:Aurolife Pharma LLC
Route:ORAL
Strength:3.75 mg in 1 1
Approved: 2024/01/20
NDC:13107-282
Clorazepate Dipotassium
Manufacturer:PD-Rx Pharmaceuticals, Inc.
Route:ORAL
Strength:15 mg in 1 1
Approved: 2024/02/16
NDC:72789-256
CLORAZEPATE DIPOTASSIUM
Manufacturer:Aurolife Pharma LLC
Route:ORAL
Strength:15 mg in 1 1
Approved: 2024/01/20
NDC:13107-284
Clorazepate Dipotassium
Manufacturer:Taro Pharmaceuticals U.S.A., Inc.
Route:ORAL
Strength:15 mg in 1 1
Approved: 2023/11/09
NDC:51672-4044
Clorazepate Dipotassium
Manufacturer:Taro Pharmaceuticals U.S.A., Inc.
Route:ORAL
Strength:3.75 mg in 1 1
Approved: 2023/11/09
NDC:51672-4042

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath